PlainPharmaWatch
CMS PY 2024 Company profile Open Payments data

ZIMMER BIOMET HOLDINGS, INC.

ZIMMER BIOMET HOLDINGS, INC. reported $88.6M in payments to physicians and teaching hospitals across 33,636 transactions in CMS Open Payments PY 2024.

Pharmaceutical payment transparency data for ZIMMER BIOMET HOLDINGS, INC.. Ranked #31 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.

Payment Overview

Total Payments

$88.6M

0.7% of all payments

Transactions

33,636

$2.6K avg

Recipients

32,760

$2.7K avg

Industry Rank

#31

of 1,797 companies

What the Data Shows for ZIMMER BIOMET HOLDINGS, INC.

In Program Year 2024, ZIMMER BIOMET HOLDINGS, INC. reported $88,597,173.74 in payments to 32,760 physicians and teaching hospitals across 33,636 individual transactions — an average of $2.6K per transaction and $2.7K per recipient. That total places ZIMMER BIOMET HOLDINGS, INC. at rank #31 out of 1,797 companies in the CMS Open Payments database, representing 0.7% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for ZIMMER BIOMET HOLDINGS, INC. spans 11 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Acquisitions" at $40.1M, accounting for 45.3% of the company's reported total and 56 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from ZIMMER BIOMET HOLDINGS, INC. received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 32,760 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.

Payment Breakdown by Type

ZIMMER BIOMET HOLDINGS, INC. made 11 types of payments. "Acquisitions" accounts for 45.3%.

Acquisitions $40.1M

45.3% · 56 transactions

Royalty or License $27.9M

31.5% · 647 transactions

Education $6.4M

7.2% · 2,891 transactions

Consulting Fee $4.8M

5.4% · 1,736 transactions

Travel and Lodging $2.2M

2.5% · 8,224 transactions

Food and Beverage $1.4M

1.6% · 18,946 transactions

Space Rental or Facility Fees $349.3K

0.4% · 41 transactions

Debt Forgiveness $264.1K

0.3% · 89 transactions

Payment Type Amount Transactions
Acquisitions $40.1M 56
Royalty or License $27.9M 647
Education $6.4M 2,891
Consulting Fee $4.8M 1,736
Travel and Lodging $2.2M 8,224
Food and Beverage $1.4M 18,946
Space Rental or Facility Fees $349.3K 41
Debt Forgiveness $264.1K 89
Compensation for Services Other Than Consulting $204.3K 27
Grant $179.8K 79
Long-Term Medical Supply or Device Loan $44.3K 24

Payment Size Analysis

Average transaction size: $2.6K. Average per recipient: $2.7K.

Total Amount

$88,597,173.74

Avg per Transaction

$2.6K

Avg per Recipient

$2.7K

Payment Transparency Context

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.3B

across 1,797 companies

ZIMMER BIOMET HOLDINGS, INC. Share

0.7%

#31 by total payments

Frequently Asked Questions

How much did ZIMMER BIOMET HOLDINGS, INC. pay to physicians and hospitals in 2024?
ZIMMER BIOMET HOLDINGS, INC. made $88,597,173.74 in payments to physicians and hospitals in Program Year 2024, across 33,636 individual transactions. This represents 0.7% of all industry payments reported to CMS Open Payments.
How many physicians received payments from ZIMMER BIOMET HOLDINGS, INC.?
ZIMMER BIOMET HOLDINGS, INC. made payments to 32,760 physicians and teaching hospitals in 2024. The average payment per recipient was $2.7K.
What types of payments did ZIMMER BIOMET HOLDINGS, INC. make?
ZIMMER BIOMET HOLDINGS, INC. made 11 different types of payments. The largest category was "Acquisitions" at $40.1M, representing 45.3% of all payments.
How does ZIMMER BIOMET HOLDINGS, INC. rank among pharmaceutical companies?
ZIMMER BIOMET HOLDINGS, INC. ranks #31 out of 1,797 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from ZIMMER BIOMET HOLDINGS, INC.?
The average transaction from ZIMMER BIOMET HOLDINGS, INC. was $2.6K in 2024. The company made 33,636 total transactions to 32,760 recipients.
Are the top recipients concentrated for ZIMMER BIOMET HOLDINGS, INC.?
The top 5 recipients received $0.00 from ZIMMER BIOMET HOLDINGS, INC., representing 0.0% of the company's total payments. Payments are relatively well-distributed across recipients.
Where does the payment data for ZIMMER BIOMET HOLDINGS, INC. come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.